Epitopea’s Off-the-Shelf mRNA Ovarian Cancer Vaccine Enters the Clinic
Biotech firm Epitopea has launched a Phase I/Ib clinical trial for its mRNA-based ovarian cancer vaccine, CryptiVax-1001. The vaccine targets 'dark genome' antigens to trigger an immune response in patients with advanced high-grade serous ovarian cancer.
Why it matters
This trial represents a novel approach to cancer immunotherapy by utilizing previously ignored genetic sequences to treat difficult-to-manage ovarian cancers.
British Canadian biotech Epitopea has begun a Phase I/Ib trial of its off-the-shelf messenger (m)RNA cancer vaccine, CryptiVax-1001, for treating women with advanced high-grade serous ovarian cancer.
The OVACT trial plans to recruit up to 30 women with this type of cancer in the U.K. to take part in the study, which will look at safety and tolerability of the vaccine, as well as early signs of efficacy.
The trial will target advanced high-grade serous ovarian cancer that is homologous recombination-proficient and does not have cancer-linked BRCA mutations. These cancers retain a particular DNA-repair capability, but generally benefit less from PARP inhibitors, an important class of maintenance treatments used to delay ovarian cancer progression.
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in